Lyra Therapeutics Inc

-0.46 (-5.08%)
Products, Strategic Combinations

Lyra Therapeutics And Lianbio Announce Strategic Partnership And Exclusive License Agreement To Develop And Commercialize Lyr-210 In Greater China And Other Asian Markets

Published: 06/02/2021 11:27 GMT
Lyra Therapeutics Inc (LYRA) - Lyra Therapeutics and Lianbio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize Lyr-210 in Greater China and Other Asian Markets.
Lyra Therapeutics Inc - Will Receive an Upfront Payment of $12 Million.
Lyra Therapeutics - is Eligible to Receive Up to $135 Million in Future Payments Based Upon Achievement of Specified Milestones.
Lyra Therapeutics Inc - Lyra Will Retain All Rights to Lyr-210 in All Other Geographies.
Lyra Therapeutics Inc - Lianbio Will Be Responsible for Clinical Development and Commercialization of Lyr-210 in Licensed Territories.